Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 73, Issue 4, Pages 942-952
Publisher
Oxford University Press (OUP)
Online
2017-11-25
DOI
10.1093/jac/dkx483
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value
- (2017) A. Oliva et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae
- (2017) Miao Zhao et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis
- (2017) Jian Li et al. Microbial Drug Resistance
- Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy
- (2017) Christina A. Sutherland et al. Journal of Thoracic Disease
- Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments
- (2017) Thomas Tängdén et al. Infectious Diseases
- Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in anIn Vitro, Hollow-Fiber Model
- (2016) Jordan R. Smith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation
- (2016) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes
- (2016) Christina A. Sutherland et al. JOURNAL OF CHROMATOGRAPHIC SCIENCE
- In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates
- (2016) Christina A. Sutherland et al. Annals of Clinical Microbiology and Antimicrobials
- Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals
- (2015) Christina A. Sutherland et al. CLINICAL THERAPEUTICS
- Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
- (2015) Tobias Bollenbach CURRENT OPINION IN MICROBIOLOGY
- In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa
- (2015) Xiuzhen Di et al. JOURNAL OF ANTIBIOTICS
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen
- (2014) Etienne de Montmollin et al. INTENSIVE CARE MEDICINE
- When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing
- (2014) C. D. Doern JOURNAL OF CLINICAL MICROBIOLOGY
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
- (2012) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands
- (2012) P. D. Croughs et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010
- (2012) Dawn M. Sievert et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Antimicrobial resistance surveillance in the AFHSC-GEIS network
- (2011) William G Meyer et al. BMC PUBLIC HEALTH
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients
- (2011) Argyris S Michalopoulos et al. Annals of Intensive Care
- Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
- (2010) Y. Ge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hospital-Acquired Infections Due to Gram-Negative Bacteria
- (2010) Anton Y. Peleg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future
- (2010) Rustam I. Aminov Frontiers in Microbiology
- Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections
- (2009) Nikos Roussos et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started